Condition

Triple Negative Breast Cancer (TNBC), Early Setting

ClinicalTrials.gov condition label

Clinical trials3

Recruiting1

Common interventions5

Lead sponsors shown3

Clinical trials

3 shown

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast CancerNCT06831955 · 2026-02-01

Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.NCT07551765 · 2026-11-13

NOT_YET_RECRUITING

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNCT07486687 · 2026-04-01

NOT_YET_RECRUITING

Common interventions

Exercise TherapyOTHER1 Fasting-Mimicking DietDIETARY_SUPPLEMENT1 SOCDRUG1 Standard of care (capecitabine or olaparib)DRUG1 Standard of care plus pembrolizumabDRUG1

Leading sponsors

Barts & The London NHS Trust1 The Netherlands Cancer Institute1 Universitaire Ziekenhuizen KU Leuven1

Trial status mix

NOT_YET_RECRUITING2

RECRUITING1

Phase mix

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.